Genomtec SA announced today that it has filed a patent application with the British Patent Office for an innovative technology for the diagnosis of single-nucleotide genetic changes. The Company’s strategy includes extending patent protection under the international PCT procedure.
“The OncoSNAAT project is progressing according to schedule, bringing us closer to creating an innovative diagnostic solution supporting oncological treatment and other applications in diagnostics. The method of detecting single-nucleotide genetic changes using isothermal amplification of nucleic acids, which we have applied for a patent for, combined with the earlier solution for the diagnosis of multi-nucleotide changes, creates a comprehensive diagnostic tool. It enables the detection of genetic variants that are key for the selection of therapy in oncology (CDx), with the potential for use in other areas of diagnostics. Filing the second patent application is a milestone in the development of our oncological project. The introduction of this technology can significantly increase the effectiveness of genetic diagnostics, which opens up new therapeutic possibilities for patients. Moreover, the potential of this method goes far beyond medicine,” said Miron Tokarski, CEO of Genomtec SA
The methodology developed by Genomtec uses modified SNAAT/LAMP technology, which enables precise diagnosis of single-nucleotide genetic changes, especially in mixtures containing both mutated and non-mutated material. This technique finds application in oncology, including in the analysis of samples using liquid biopsy technology, as well as in other fields, such as veterinary medicine or food safety. This technology enables comprehensive diagnosis of genetic changes that are of key clinical importance, including in the selection of oncological therapies. In the Company’s opinion, obtaining patent protection will strengthen its position in the M&A process.
